PRESS-RELEASE filed Jul 15, 2026 at 07:00 ET
Axsome Therapeutics announced FDA acceptance of its NDA for AXS-12 (reboxetine) to treat cataplexy in narcolepsy, with a PDUFA target action date of May 1, 2027. The FDA does not currently plan to hold an advisory committee meeting, which reduces regulatory uncertainty. This is a procedural milestone for a mid-stage pipeline asset, not a revenue-generating event, and the stock's historical reaction to neutral filings has been negative on average.